IMB1603, a new benzothiazinone lead discovered by our lab, exhibited potent anti-MTB activity in vitro and in vivo, but significant hERG binding potency (IR > 90% at 10 μM). Thus, we embarked on a lead optimization program with the goal of identifying alternative leads that could reduce the hERG liability without sacrificing antimycobacterial potency. Compounds 2c and 4c were identified to maintain the anti-MTB activity (MICs <0.035-0.078 μM), and had lower hERG binding affinity (IR < 50% at 10 μM). Both of them were also found to have acceptable safety and pharmacokinetic properties. Studies to determine the in vivo efficacy of 2c and 4c are currently underway.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ejmech.2019.06.053 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Screening, Discovery, and Optimization of the Natural Antitubercular Chlorflavonin from a Marine-Derived Fungal Library.
J Nat Prod
January 2025
Key Laboratory of Marine Drugs, The Ministry of Education of China, School of Medicine and Pharmacy, Ocean University of China, Qingdao 266003, People's Republic of China.
Tuberculosis (TB), caused by the bacterium (), is still a leading cause of mortality worldwide. Fifty-fungi from a marine-derived fungal library were screened for anti- activity, and an strain with strong anti- activity was found. Three known flavones, chlorflavonin (), dechlorflavonin (), and bromoflavone (), were isolated from this fungus.
View Article and Find Full Text PDFFunctionalized regioisomers of the natural product phenazines myxin and iodinin as potent inhibitors of Mycobacterium tuberculosis and human acute myeloid leukemia cells.
Eur J Med Chem
January 2025
School of Health Sciences, Faculty of Pharmaceutical Sciences, University of Iceland, Hofsvallagata 53, IS-107, Reykjavik, Iceland. Electronic address:
The natural bioactive products myxin and iodinin are phenazine 5,10-dioxides possessing potent anti-bacterial and anti-cancer activity in vitro. This work describes the synthesis and derivatization of new myxin and iodinin regioisomers, developed from 1,3-dihydroxyphenazine 5,10-dioxide. Compounds were evaluated for activity towards M.
View Article and Find Full Text PDFMachine learning-enabled virtual screening indicates the anti-tuberculosis activity of aldoxorubicin and quarfloxin with verification by molecular docking, molecular dynamics simulations, and biological evaluations.
Brief Bioinform
November 2024
Institute of Medical Information, Chinese Academy of Medical Sciences and Peking Union Medical College, Chaoyang District, Beijing 100020, China.
Drug resistance in Mycobacterium tuberculosis (Mtb) is a significant challenge in the control and treatment of tuberculosis, making efforts to combat the spread of this global health burden more difficult. To accelerate anti-tuberculosis drug discovery, repurposing clinically approved or investigational drugs for the treatment of tuberculosis by computational methods has become an attractive strategy. In this study, we developed a virtual screening workflow that combines multiple machine learning and deep learning models, and 11 576 compounds extracted from the DrugBank database were screened against Mtb.
View Article and Find Full Text PDFAntimycobacterial Activity of Solid Lipid Microparticles Loaded with Ursolic Acid and Oleanolic Acid: In Vitro, In Vivo, and Toxicity Assessments.
Microorganisms
October 2024
Nanobios Lab, Department of Biosciences and Bioengineering, Indian Institute of Technology Bombay, Mumbai 400076, India.
Article Synopsis
- Ursolic acid (UA) and oleanolic acid (OA) are natural compounds with anti-mycobacterial properties but have poor solubility, limiting their use in treatment.
- Researchers developed solid lipid microparticles (SLMs) to effectively deliver UA and OA, demonstrating their ability to inhibit both drug-sensitive and multidrug-resistant tuberculosis (Mtb) in lab tests.
- In mouse models, the delivery of SLMs via inhalation significantly reduced bacterial loads and improved survival rates without causing toxicity, showcasing their potential as a safe and effective treatment option for tuberculosis.
A new -acylhydrazone oxadiazole derivative with activity against mycobacteria.
Future Microbiol
January 2025
Postgraduate Program of Biosciences and Physiopathology, Department of Clinical Analysis and Biomedicine, State University of Maringa, Maringa, Parana, Brazil.
Article Synopsis
- - The study evaluated a new hybrid compound derived from oxadiazol-4-methoxynaphthalene for its potential to inhibit a specific virus and clinical isolates, alongside its interaction with anti-tuberculosis drugs.
- - Researchers determined the minimal inhibitory concentration, conducted time kill curve assays, and assessed pharmacokinetics and cytotoxicity to understand the effectiveness and safety of the compound.
- - The findings suggest that the newly synthesized molecule shows promising anti-viral activity with low toxicity, making it a candidate for further development as an anti-TB drug.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!